Thrombolysis for stroke in India: Miles to go...

Neurology India

Volumn 55, Issue 1, 2007, Pages 3-5

  Murthy, J M K ^a  

^a CARE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

CEREBROVASCULAR ACCIDENT; COST CONTROL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDITORIAL; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; INDIA; MOTORIZED TRANSPORT; PATIENT TRANSPORT; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; STROKE; TREATMENT OUTCOME;

EID: 33846957121     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: 10.4103/0028-3886.30415     Document Type: Editorial

References (27)

1. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003;362:1211-24.
2. Asia Pacific Consensus Forum on stroke management. Stroke 1998;29:1730-6.
3. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality and mortality in the WHO MONICA project. Stroke 1995;26:361-7.
4. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
5. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev 2003:3:CD000213.
6. The SITS Collaborators. Thrombolysis for acute ischemic stroke: Main outcome results for 2003-2005 of SITS-MOST (safe implementation of thrombolysis in stroke-monitoring study) in Europe. Cerebrovasc Dis 2006;21:1-151.
7. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832-40.
8. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-utility analysis of tissue plasminogen activator therapy for acute ischemic stroke. Pharmacoeconomics 2001;19:927-36.
9. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-7.
10. Moodie ML, Carter R, Mihalopoulos C, Thrift AG, Chambers BR, Donnan GA, et al. Trial application of a Model Of Resource Utilization, Costs and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004;35:1041-6.
11. Fagan S, Morgenstern L, Pettita A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-90.
12. Chambers M, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002;5:85-97.
13. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke. J Clin Epidemiol 1999;52:259-71.
14. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36:2500-3.
15. Nilasena DS, Kreskowik TF, Wiblin RT. Assessing patterns of tPA use in acute stroke. Stroke 2002;33:354.
16. The World Bank, Entering the 21st century. World Development Report: 1999/2000. Oxford University Press: New York; 2000.
17. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64:654-9.
18. Weir NU, Bachan AM. A study of the workload and effectiveness of a comprehensive acute stroke service. J Neurol Neurosurg Psychiatry 2005;76:863-5.
19. Pandian JD, Padma MV, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke 2007;2:17-26.
20. Available from: http://rbidocs.rbi.org.in/rdocs/Publications/PDFs/ 72631.pdf.
21. Padma MV, Singh MB, Bhatia R, Srivastava A, Tripathi M, Shukla G, et al. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 2007;55:46-9.
22. Pandian JD, Sethi V, Dhillon R, Kaur R, Padala S, Chakravorty R, et al. Is intravenous thrombolysis feasible in a developing country? Cerebrovasc Dis 2005;20:134-6.
23. Nandigam K, Narayan SK, Elangovan S, Dutta TK, Sethuraman KR, Das AK. Feasibility of acute thrombolytic therapy for stroke. Neurol India 2003;51:470-3.
24. Srivastava AK, Prasad K. A study of factors delaying hospital arrival of patients with acute stroke. Neurol India 2001;46:272-6.
25. Pandian JD, Kalra G, Jaison A. Factors delaying admission to a hospital-based stroke unit in India. Cerebrovasc Dis 2006;15:81-7.
26. Pandian JD, Kalra G, Jaison A, Deepak SS, Shamsher S, Singh Y, et al. Knowledge of stroke among stroke patients and their relatives in northwest India. Neurol India 2006;54:152-6.
27. Pandian JD, Jaison A, Deepak SS, Kalra G, Shamsher S, Lincoln DJ, et al. Public awareness of warning symptoms, risk factors and treatment of stroke in northwest India. Stroke 2005;36:644-8.